Related Experiment Videos
Cost-effectiveness of sumatriptan in a managed care population
The American Journal of Managed Care
|December 8, 1996
Summary
Sumatriptan treatment significantly reduced migraine severity and disability days. This migraine therapy also lowered healthcare costs for health maintenance organizations, proving more cost-effective.
Area of Science:
- Pharmacoeconomics
- Neurology
- Health Services Research
Background:
- Migraine headaches represent a significant health burden, impacting quality of life and healthcare utilization.
- Evaluating the cost-effectiveness of migraine treatments is crucial for optimizing healthcare resource allocation.
Purpose of the Study:
- To assess the cost-effectiveness of sumatriptan compared to other migraine therapies.
- To analyze the impact of sumatriptan on healthcare costs and patient-reported migraine disability.
Main Methods:
- An open-labeled study involving 164 sumatriptan users from a health maintenance organization.
- Telephone surveys were used to collect data on healthcare costs and migraine disability days before and after sumatriptan treatment.
Main Results:
- Sumatriptan use decreased severe migraine prevalence from 89% to 63%.
- Monthly migraine disability days reduced from 6.5 to 3.9 days.
- Healthcare utilization and total migraine-related expenditures decreased by 41%, with a 47% improvement in cost-effectiveness.
Conclusions:
- Sumatriptan is a cost-effective treatment for migraine headaches.
- Sumatriptan therapy leads to reduced patient disability, lower healthcare resource utilization, and improved overall cost-effectiveness for health maintenance organizations.